NCT07818772

7T Imaging Pilot-study in Patients With Motor Neuron Disease to Find Non-Invasive Disease Imaging Biomarkers

StatusRecruiting

PhaseNot specified

SponsorNHS Greater Glasgow and Clyde

Primary completionNov 30, 2026 (estimated)

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

Sep 9, 2026 Study First Submitted

Endpoints

Primary

Demonstration of Pathology on 7T MRI

Timeframe: 2 years

Secondary (2)

Tolerability of 7 T scanning by ALS patients.

Quality of MRI imaging of ALS patients by 7T system.

Arms and interventions

Standard Coil

ALS cases

Head and Neck coil

ALS cases

Devices: MRI

Sites

1 site in 1 country

ICE BuildingGlasgow, United Kingdom

About this trial

Motor Neuron Disease (MND) is a neurodegenerative disorder, which causes progressive loss of nerve cells controlling the muscles responsible for movement, speech, swallowing and breathing. MND is not actually a single disease, but a range of diseases; some more serious with patients dying within a year, and some less severe cases with a life expectancy of several years. It is often difficult and can take a long time to get a diagnosis of MND, by which time patients are often already very unwell. The aim of this research study is to improve the diagnosis of MND and make it faster. The investigators plan to achieve this goal by using advanced Magnetic Resonance Imaging (MRI) to develop new diagnostic tests for MND. The investigators will use a scanner with a very strong magnetic field of 7 tesla (7T), which provides images of the brain with increased detail compared to standard MRI scanners, which use magnetic field strengths of 1.5T or 3T. The investigators will use the advanced capability of 7T MRI to identify so-called imaging biomarkers, which are features of the scans that are specific to a particular disease, in this case MND and its different subtypes. This is a pilot study with a relatively small number of patients. The preliminary findings from this research will be used to design larger follow-on studies aiming to establish a fast and specific diagnosis for patients living with MND. This would allow patients to enter suitable trials faster and would help patients to receive more tailored treatment.

Trial details

Enrollment: 30 participants (estimated)
Started: Apr 13, 2026
Study completion: Nov 30, 2026 (estimated)
Eligibility: 18 and older, all sexes, no healthy volunteers
Design: Observational
Oversight: No data monitoring committee
Conditions: Amyotrophic Lateral Sclerosis, ALS - Amyotrophic Lateral Sclerosis
Collaborators: NHS Greater Glasgow and Clyde Board HQ
First posted: Sep 14, 2026
Registry updated: Sep 14, 2026
Last verified: Jul 2026

Related trials at risk

View on ClinicalTrials.gov ↗